Caregivers' Perspectives on the Impact of Cannabidiol (CBD) Treatment for Dravet and Lennox-Gastaut Syndromes: A Multinational Qualitative Study

被引：11
作者：
Marshall, Jade [1 ]
Skrobanski, Hanna [2 ]
Moore-Ramdin, Lisa [1 ]
Kornalska, Klaudia [2 ]
Swinburn, Paul [2 ]
Bowditch, Sally [1 ,3 ]
机构：
[1] Jazz Pharmaceut Inc, London, England
[2] Acaster Lloyd Consulting Ltd, London, England
[3] Jazz Pharmaceut Inc, 1 Cavendish Pl, London W1G 0QF, England
来源：
JOURNAL OF CHILD NEUROLOGY | 2023年
关键词：
antiseizure drugs; behavior; epilepsy; quality of life; seizures; PATIENT-REPORTED OUTCOMES; OF-LIFE; OPEN-LABEL; COMORBIDITIES; SEIZURES; TRIAL; EXPERIENCE; MANAGEMENT; MORTALITY; EPILEPSY;
D O I：
10.1177/08830738231185241
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Objective: To increase understanding of the impact of cannabidiol (CBD) on outcomes beyond seizure control among individuals with Dravet syndrome or Lennox-Gastaut syndrome. Methods: Qualitative interviews were conducted with caregivers of individuals with Dravet syndrome or Lennox-Gastaut syndrome treated with plant-derived, highly purified CBD medicine (Epidiolex in the USA; Epidyolex in Europe; 100 mg/mL oral solution). Symptoms and impacts of Dravet syndrome and Lennox-Gastaut syndrome on individuals were explored, as were the effects of CBD. Data were analyzed using thematic analysis. Results: Twenty-one caregivers of individuals with Dravet syndrome (n = 14) and Lennox-Gastaut syndrome (n = 7) aged 4-22 years participated. Health-related quality of life improvements associated with CBD included cognitive function, communication, behavior, mobility, and participation in daily activities. Seizure frequency reduction was commonly reported (n = 12), resulting in caregivers having greater freedom and family life being less disrupted. Adverse events were reported by 10 caregivers. Conclusion: In addition to reduced seizure frequency, CBD may have a wide range of beneficial effects beyond seizure control that warrant further investigation.
引用
收藏
页码：394 / 406
页数：13
相关论文
共 50 条
[21]   Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study [J].
Thiele, Elizabeth ;
Marsh, Eric ;
Mazurkiewicz-Beldzinska, Maria ;
Halford, Jonathan J. ;
Gunning, Boudewijn ;
Devinsky, Orrin ;
Checketts, Daniel ;
Roberts, Claire .
EPILEPSIA, 2019, 60 (03) :419-428
[22]   Seizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey [J].
Saurer, T. ;
Berg, A. ;
Dixon-Salazar, T. ;
Meskis, M. ;
Danese, S. ;
Le, N. ;
Perry, M. .
ANNALS OF NEUROLOGY, 2023, 94 :S54-S54
[23]   Nonseizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey [J].
Dixon-Salazar, T. ;
Berg, A. ;
Meskis, M. ;
Danese, S. ;
Saurer, T. ;
Le, N. ;
Perry, M. .
ANNALS OF NEUROLOGY, 2023, 94 :S54-S55
[24]   Time to Onset of Efficacy of Cannabidiol (CBD) During Titration in Patients with Lennox-Gastaut Syndrome (LGS) or Dravet Syndrome (DS) Enrolled in Three Randomized Controlled Trials [J].
Marsh, E. ;
Privitera, M. ;
Mazurkiewicz-Beldzinska, M. ;
Villanueva, V. ;
Checketts, D. ;
Knappertz, V .
ANNALS OF NEUROLOGY, 2019, 86 :S69-S70
[25]   Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex [J].
Strzelczyk, Adam ;
Klotz, Kerstin Alexandra ;
Mayer, Thomas ;
von Podewils, Felix ;
Knake, Susanne ;
Kurlemann, Gerhard ;
Herold, Luise ;
Immisch, Ilka ;
Buhleier, Elisa ;
Rosenow, Felix ;
Schubert-Bast, Susanne .
NEUROLOGY AND THERAPY, 2025,
[26]   The emotional burden of caring for patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex-associated epilepsy: A qualitative study in Japan [J].
LoPresti, Michael ;
Igarashi, Ataru ;
Sonohara, Yaoki ;
Bowditch, Sally .
EPILEPSY & BEHAVIOR, 2024, 158
[27]   Cannabidiol (CBD) Treatment Effect and Adverse Events (AEs) by Time in Patients with Lennox-Gastaut Syndrome (LGS): Pooled Results from 2 Trials [J].
Wirrell, E. ;
Privitera, M. ;
Bhathal, H. ;
Wong, M. ;
Cross, J. ;
Sommerville, K. .
ANNALS OF NEUROLOGY, 2018, 84 :S341-S341
[28]   Real-world evidence on the use of cannabidiol for the treatment of drug resistant epilepsy not related to Lennox-Gastaut syndrome, Dravet syndrome or Tuberous Sclerosis Complex [J].
Espinosa-Jovel, Camilo ;
Riveros, Sandra ;
Bolanos-Almeida, Carlos ;
Salazar, Mateo Ramirez ;
Inga, Leidy Ceballos ;
Guio, Laura .
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2023, 112 :72-76
[29]   Treatment Guidelines for Rare, Early-Onset, Treatment-Resistant Epileptic Conditions: A Literature Review on Dravet Syndrome, Lennox-Gastaut Syndrome and CDKL5 Deficiency Disorder [J].
Chin, Richard F. ;
Mingorance, Ana ;
Ruban-Fell, Benjamin ;
Newell, Isabelle ;
Evans, Jenni ;
Vyas, Kishan ;
Nortvedt, Charlotte ;
Amin, Sam .
FRONTIERS IN NEUROLOGY, 2021, 12
[30]   Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal [J].
Wijnen, Ben ;
Armstrong, Nigel ;
Ramaekers, Bram ;
Witlox, Willem ;
Westwood, Marie ;
Fayter, Debra ;
Ryder, Steve ;
Buksnys, Titas ;
Worthy, Gill ;
Misso, Kate ;
Grimm, Sabine ;
Kleijnen, Jos ;
Joore, Manuela .
PHARMACOECONOMICS, 2020, 38 (10) :1043-1053
12345